Global Investor Forum Contact

Erik van den Berg

CEO, AM-Pharma

Session(s)

11:30 - 12:45 hours
IP Valuation

13:15 - 14:00 hours
GIF Leadership session

Erik has over seventeen years experience in the pharmaceutical and biotechnology industries. He joined AM-Pharma in September 2007 as Chief Business Officer and became the company's CEO in 2011.

Previously, as a Senior Executive at Organon (NL) he was responsible for leading the Company’s global biotechnology business development. At Organon, he also held European Business Development as well as Marketing and Sales roles relating to the Company’s biotechnology services.

Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships and raised more than €130M in equity and debt financing for biotechnology companies. He is also the founder and board member of two high-tech start-up companies.

Erik has a MSc in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK).

Abstract

Academia and industry – doomed relationship?
Academic research institutes are cradles of knowledge and inventions, sometimes resulting in successful products that are commercialized by industry. Collaborations between academia and industry are not always easy. There may be a different appreciation of the length and risk of the development process needed to transform an invention into a successful product. This may result in different expectations as to the value of the invention. These opposing perspectives may complicate a fruitful collaboration. But what formats can lead to mutual benefit? Do both partners need each other? Is it important to patent the invention, and what rules for ownership may apply? In this track, representatives from both sides will give their opinion on requirements for a successful collaboration.

Kees Been
Lysosomal Therapeutics Inc.

Erik van de Berg
AM-Pharma

René Bernards
Qameleon Therapeutics & NKI

Annelien Bredenoord
UMC Utrecht

Carine van den Brink
AXON Lawyers

Danielle Curfs
Chemelot InSciTe
Jenny Dankelman
TU Delft
Diederik Dippel
Erasmus MC

Cornelia van Duijn
Erasmus MC

Lude Franke
UMCG
Thibault Helleputte
DNAlytics
Mark van Houdenhoven
St. Maartenskliniek
Henk Joos
Flanders Bio
Peter de Keizer
Erasmus MC
Tim Knotnerus
AM-Pharma, PRIMER Professionals
Angus Livingstone
Oncode Institute
Travis McCready
Massachusetts Life Sciences Center

Mirjam Mol
Pivot Park

Barend Mons
DTL & LUMC
Timothy Noël
Eindhoven University of Technology
Jacquelien Noordhoek
Dutch CF Foundation
Violet Petit-Steeghs
Athena Institute
Thomas Plochg
NPHF
Dirk Jan van der Pol
Ordina
Anne Portwich
LSP
Elisabeth van Rossum
Erasmus MC
André van de Sande
Xendo
Marlies Schijven
AMC
Hans Schikan
Topsector LSH
Hanneke Schuitemaker
Janssen Vaccines
Frits Schut
V.O. Patents & Trademarks
Marieke Schuurmans
UMC Utrecht
Jacob Seidell
VU
Agaath Sluijter
Medical Delta
Thijs Spigt
Erasmus MC
Marianne van der Steen
Maastricht University
Maarten Steinbuch
Eindhoven University of Technology
Onno van de Stolpe
Galapagos
Werner Verbiest
Janssen Diagnostics
Martine de Vries
LUMC

Edward van Wezel
BioGeneration Ventures

Jan van de Winkel
Genmab

Loek Winter
DC Klinieken

Hanneke Heeres
Health~Holland
Caroline Duterloo
Medical Delta
Paul Korte
Janssen
Aart Jan van der Lelij
Erasmus MC
Werner Brouwer
Erasmus University
Arnout van Diermen
Novo Nordisk
Sponsors & Partners
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Award sponsor
Award sponsor
© 2017 Innovation for Health